Police & medics targetted first in global experiment.
The death of Joao Pedro Feitosa aroused deep emotion in the Federal University of Rio de Janeiro where he had been a student of the principal Denise Pires de Carvalho.
“The Rectorate of the UFRJ – together with the entire university community – offers sincere condolences to the family and friends of our former student in the midst of this moment of sadness that took the life of João, who had just graduated and did not spare efforts to act in tackling the COVID-19 pandemic, which has accumulated over 40 million cases around the world ”.
The Brazilian online media then cites a study with preliminary results of the Oxford vaccine (AZD1222) was published July 20 in the scientific journal “The Lancet”. Research cites reactions that are considered mild and moderate and does not mention serious side effects: Pain after vaccination: 67% without paracetamol; 50% with paracetamol. Tiredness: 70% without paracetamol; 71% with paracetamol. Headache: 68% without paracetamol; 61% with paracetamol. Muscle pain: 60% without paracetamol; 48% with paracetamol.
….On the same day that international agencies communicate this mysterious death, which is added to the two cases of the British with serious adverse reactions, by a curious coincidence the president of the biotechnology company IRBM of Pomezia Terme (Italy, nera Rome), the former lobbyist and television producer Piero di Lorenzo, trusted by the governor of Lazio Nicola Zingaretti, major financier of the research center, announces the imminent arrival of the Oxford-AstraZeneca vaccine in Italy at the beginning of December which will be destined for the most at-risk groups of the population such as the elderly of the nursing health home.
As Ansa recalls, the availability of the first doses by December, already announced in recent days by the Prime Minister Giuseppe Conte, was thus confirmed by Di Lorenzo “if no sudden problems arise – he said during an interview granted to the Financial Lounge website – it is reasonable to think that the clinical trial phase could be completed by the end of November or early December “. Italy could receive 2-3 million doses to be initially distributed among health workers, law enforcement and hospices guests.